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Endocrine-disrupting chemicals (EDCs) are exogenous compounds that impact
endogenous hormonal systems, resulting in adverse health effects. These chemicals
can exert their actions by interfering with several pathways. Simple biological systems to
determine whether EDCs act positively or negatively on a given receptor are often lacking.
Here we describe a low-to-middle throughput method to screen the agonist/antagonist
potential of EDCs specifically on the GPER membrane estrogen receptor. Application of
this assay to 23 candidate EDCs from different chemical families reveals the existence of
six agonists and six antagonists.
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INTRODUCTION
Endocrine-disrupting chemicals (EDCs) can be defined as exogenous compounds that can interfere
with hormonal signaling (1). Chemicals classified as EDCs are produced for various industrial
purposes (for example as components of pesticides, cosmetic products or plastic components) and
belong to different chemical families (for example alkylphenols, parabens or phthalates). EDCs can
accumulate in the environment (with varying levels of persistence), diet as well as body fluids and
tissues. The adverse health effects elicited by EDCs can be diverse. For instance, as evaluated by
epidemiological studies and/or experimental set up, exposure to Bisphenol A (BPA, a prototypical
EDC) is correlated with increased cancer risk, obesity and reproductive health defects (2–5). EDCs
can impact diverse levels of endocrine signaling, ranging from hormone production to hormone
receptor expression and downstream signaling. Mechanistically, their action can be mediated by
several receptors onto which they act as agonists or antagonists. For instance, BPA has been
reported to dysregulate the activity of several nuclear receptors, such as the estrogen receptors
(ERs), androgen receptor (AR) or estrogen-related receptor γ (ERRγ) [(6–11); reviewed in (12)].
EDC receptors are often co-expressed in given cells and tissues, complicating the mechanistic
interpretation of the results. As a consequence, determining whether an EDC targets a given
receptor leading to the dysregulation of discrete pathway(s), can be a laborious task. There is thus a
need for simple systems in which a measurable effect can be directly ascribed to the (dys)regulation
of a single receptor/pathway.
G protein-coupled estrogen receptor (GPER, previously known as GPR30 or GPER1) is a
membrane-localized receptor with capacities to bind estrogens (13–15) and to crosstalk with the
classical nuclear estrogen receptors (16, 17). GPER signaling is involved in various physiological
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and pathological processes such as metabolic regulations,
diabetes and atherosclerosis, or cancer progression (18–21),
suggesting that it could contribute, at least in part, to some
of the adverse effect of EDCs. In support to this hypothesis,
studies at the cellular level have shown that, in addition to
endogenous estrogens, GPER activity can be modulated by
several compounds including synthetic selective agonists or
antagonists (e.g., G-1 or G-15 and G-36, respectively), selective
estrogen receptor modulators (SERMs) and bisphenols (22–
25). Altogether, this suggests a capacity of GPER to respond
to a broad spectrum of chemicals, including EDCs, many
of which remain unknown. This also points to the need of
defining a simple test to easily identify agonists/antagonists of
this pathway.
Our previous work (26) showed that primary human
dermal fibroblasts (hDF), which do not express ER, display a
quantifiable morphological change in response to 17β-estradiol
(E2), in a strict GPER-dependent manner. This suggested
that this cellular phenomenon could be used as a read-
out of GPER activation. However, primary cultures originate
from different donors. Thus, inter-individual variability in
the response as well as a possible exhaustion of the cell
batches, may jeopardize reproducibility and efficiency. Using
the MRC5 human fibroblast cell line, we here report the
establishment of amethod for a low-to-middle throughput screen
of compounds acting on GPER as agonist or antagonist. We
apply this cell-based method to define the capacity (or lack




Cells were cultured in DMEM supplemented with 10% FCS, 10
U/ml penicillin and 10µg/ml streptomycin (complete medium).
For proliferation tests and evaluation of compound toxicity, 2 ×
104 MRC5 cells were seeded in 96-well plates and assessed for cell
number using CellTiterGlo kit (Promega).
For cell shape studies using the Cytonote lens-free cell
imaging device (Iprasense, Montpellier, France), 10,000 MRC5
cells were seeded in 400 µl of complete medium in 4-
chambers culture dishes. After 24 h, medium was changed
to 600 µl phenol red-free DMEM without serum and cells
were further incubated for 48 h. Ten microliter phenol red-
free medium containing the tested compound were then added
and cell cultures were immediately analyzed for 3 or 4 h
in the Cytonote system. ImageJ was used to analyze the
reconstituted images of the cell cultures at time point 0, 60,
120, 180, and 240min after compound addition. Except were
indicated, 30 cells per experiment were individually followed
at all these time points, at which the ratio long axis to short
axis was measured. Suspected antagonists were added 15min
before agonists.
For immunofluorescence experiments, cells (40% confluent)
were cultured on glass slides, fixed with 4% paraformaldehyde
and then washed with PBS 1x. FITC-phalloidin (P5283, Sigma,
1/750) was then added for 1 h. Nuclei were counterstained
with Hoescht staining. Pictures were taken with Zeiss-Axiovert
and images were processed and analyzed with the open-source
package ImageJ with custom plug-in routines.
Compounds
All compounds used were resuspended in DMSO in 1,000x
stock solutions. Characteristics and provenance of EDCs used
in this study are shown on Table S1. 17β-estradiol (E2) was
purchased from Sigma-Aldrich, G-1 from Cayman, G-15 and
G-36 from Tocris.
Expression Analyses
For siRNA transfection, 3 × 10−5 cells per ml were seeded
in 6-well plate and 25 pmol/ml of siRNA were transfected
with INTERFERin (Polyplus Transfection) according to the
manufacturer’s recommendations.
For Western blot analysis, cells were lysed in NP40 buffer
supplemented with Protease Inhibitor Cocktail (Sigma Aldrich).
Proteins (50 µg) were resolved on 10% SDS-PAGE, blotted
onto PVDFmembrane (GE-Healthcare) and probed with specific
antibodies after saturation. Primary antibodies used in this study
were: hsp90 (API-SPA-830, Enzo Life Sciences, 1/3,000), ERα (sc-
8002 F-10 Santa Cruz, 1/1,000), and GPER (sc-48525-R, Santa
Cruz, 1/500). Secondary antibodies were: anti-rabbit IgG for
ERα and GPER, anti-mouse IgG for hsp90 (W4011 and W402B,
respectively; Promega, 1/10,000).
Total RNAs were extracted by the guanidinium
thiocyanate/phenol/chloroform method. One microgram of
RNA was converted to first strand cDNA using the RevertAid
kit (ThermoScientific). Real time PCRs were performed in
96-well plates using the IQ SYBR Green Supermix (BioRad).
Data were quantified by 11-Ct method and normalized to
36b4 expression.
Sequences of the PCR primers used in this study:
36b4: 5′-GTCACTGTGCCAGCCCAGAA-3′ and 5′-TCA
ATGGTGCCCCTGGAGAT-3′
GPER: 5′-AGGGACAAGCTGAGGCTGTA-3′ and 5′-GTC
TACACGGCACTGCTGAA-3′
Sequences of the siRNA used in this study:
GPER#1: 5′-GGCUGUACAUUGAGCAGAA-3′ and 5′-UUC
UGCUCAAUGUACAGCC-3′
GPER#2: 5′-AGCUGAGGCUGUACAUUGA-3′ and 5′-UCA
AUGUACAGCCUCAGCU-3′
Statistical Analyses
Distribution of L/s Ratio Over Cells
Using data from the E2 (10−7 M) condition obtained on 244 cells,
the L/s ratio data distribution was examined using the Shapiro-
Wilk normality test. The distribution of L/s ratios observed at
each time, as well as the distribution of L/s ratio differences
between two exposure times for each cell were found significantly
non normal (p < 10−5). In addition, homogeneity of variance
was tested with the Levene’s test. It showed that variance of L/s
ratio differences between two times significantly differs (p <
10−8). Therefore, L/s ratio was summarized by its median over
cells for each condition and only non-parametric statistical tests
were used.
Frontiers in Endocrinology | www.frontiersin.org 2 August 2020 | Volume 11 | Article 547
Périan et al. GPER and Endocrine-Disrupting Chemicals
FIGURE 1 | 17β-estradiol induces a morphological change in MRC5 cells in a GPER-dependent manner. (A) Expression of the indicated proteins was determined in
MCF7 and MRC5 cells by Western blot. Hsp90 was used as a loading control. Significance relative to time 0 (or between times 120 and 240, as indicated) was
analyzed using Wilcoxon signed-rank test. ***p < 0.0005. (B) MRC5 cells were cultured in the presence of untreated (FCS), or desteroidated serum-containing
medium supplemented with vehicle (DS) or 10−7 M 17β-estradiol (E2). (C) MRC5 cells were treated with 10−7 M G-1, a GPER agonist. (D) Cells were treated with
10−8 M E2 and/or 10−7 M G-15, a GPER antagonist. Actin and nuclei were stained. Ratio between the long and short cell axes was determined using ImageJ. Data
are expressed relative to the median ratio under DS conditions. (B) n = 10; (C) n = 30; (D) n = 60. Significance was determined using Mann-Whitney test. ***p <
0.0005; ns: non significant. Scale bar: 50 µm.
L/s Ratio Normalization
For each condition, individual L/s ratios were expressed as
relative to the median value at exposure time 0 min.
Comparing L/s Ratios
The comparison of L/s ratios between more than 2 exposure
times used the non-parametric Friedman test for repeated
measures. Post-hoc tests between two times used the Wilcoxon
signed-rank test with Bonferroni p-value correction. When
considering L/s ratios for 2 exposure times, the Wilcoxon signed
rank test was used. The comparison of L/s ratios between several
conditions or experiments at exposure time 180 used the Kruskal-
Wallis test followed by the Mann-Whitney test for comparison
between 2 groups. Statistical significance was taken at p < 0.05.
RESULTS
To extend our previous findings to amodel cell line, we examined
the estrogenic response of MRC5 cells, an immortalized human
fibroblast cell line. Western blot analysis first showed that these
cells indeed express GPER, but not the classical estrogen receptor
α (Figure 1A). As expected, both receptors were found expressed
in the human mammary cell line MCF7. The effect of E2 on
the morphology of MRC5 cells was next examined (Figure 1B).
To this end, cells were exposed to culture medium containing
untreated serum (FCS, Fetal Calf Serum) or desteroidated serum
(DS) supplemented or not with E2. After fixation, actin was
labeled to visualize cell morphology. The longest and shortest
cell axes (L and s, respectively) were measured and cell shape
was expressed as the ratio (L/s) between these axes. We noted
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a more elongated shape (i.e., high L/s ratio) in cells exposed to
DS medium, as compared to FCS-exposed cells. Interestingly,
E2 supplementation reversed this phenotype. It is unlikely that
this phenomenon involves cell proliferation. Indeed, whereas
proliferation of MRC5 cells was abolished in DS medium as
compared to FCS one, E2 addition did not reverse this effect
(Figure S1A).
These data suggest that E2 promotes MRC5 cell spreading
in a GPER-dependent manner. To prove this dependence,
we first searched to inactivate GPER in MRC5 cells, using
siRNAs. However, these siRNAs were efficient at the RNA-
but not at the protein level (Figure S1B), suggesting a high
stability of GPER protein and preventing the use of siRNAs
in our experiments. We thus turned to a pharmacological
approach. We observed that exposure to G-1, a GPER synthetic
agonist, efficiently reduces cell elongation (Figure 1C). We
also used G-15, a GPER synthetic antagonist (Figure 1D). By
itself, this compound is unable to induce any morphological
change in MRC5. However, G-15 efficiently blocks the E2-
induced cell spreading, indicating that GPER mediates this
estrogenic response. Altogether, MRC5 cells display E2-
responses that are similar to primary hDF and could thus
be used to measure GPER activation without interference
from ERα.
However, the above method measures cell shape at
experimental end-point and thus does not provide a dynamic
view of cell shape changes at an individual level. To circumvent
these limitations, we used a lens-free, live-cell imaging device that
allows the monitoring of a large number of cells. Images obtained
with this system were then analyzed to determine changes in
the L/s ratio of individual cells according to treatment. To set
up the experimental conditions, MRC5 cells were first seeded
in FCS-containing medium and then switched to serum-free
medium (Figure S2A). A significant cell elongation was observed
12 h after medium change, a phenomenon that endured for at
least 48 h. For all subsequent experiments, treatment was thus
applied after 48 h incubation in serum-free medium. Under these
conditions, addition of E2 (10−7 M) resulted in a significant
reduction of L/s ratio, as measured on 244 cells, that was obvious
120 and 240min after treatment initiation (Figure 2A). We
next wanted to determine the minimal number of cells to be
measured that would allow to reaching statistical significance.
To this end, we randomly sampled 100 sets of 10, 30, 40, 50,
60, 80, 100, or 200 cells from our initial 244-cell data set.
Medians of L/s ratio were calculated for each extracted sample.
As expected, the dispersion of the medians decreases when
increasing the sample size (Figure 2B). Medians of the 10-cell
samples at a given time point are sometimes found overcrossing
the 244-cell median at another time point. Thus, the analysis of
only 10 cells in a given experiment could lead to false negative
results. This effect was not observed for samples comprising 30
cells or more.
Statistical significances of the changes observed in the L/s
medians were then determined on the same data sets (Figure 2C).
Again, data sets comprising 10 cells often failed to reach
significance (i.e., p < 0.05). In contrast, the use of 30-cell data
sets allowed to reaching significance at the global level, i.e.,
considering all three time points together. This was also the case
when comparing time points two-by-two, except for the smaller
variations between 120 and 240min. An additional experiment
set with expanded time points showed a continuous reduction
of L/s ratio along exposure time (Figure S2B). However, the
difference between 180 and 240min after E2 addition, although
statistically significant, was much reduced. This indicates that
recording cell shape up to 180min after treatment initiation
is fairly sufficient to observe a statistically significant effect.
Under these conditions, supplementation with DMSO, the
vehicle used for E2 as well as for all hereafter used compounds,
did not impact L/s ratio (Figure S2C). We next tested the
reproducibility of our observation. To this end, we performed
three independent experiments and observed similar reduction
of L/s ratio upon E2 treatment, whereas DMSO had no effect
(Figure S2D). Importantly, the L/s values reached after 180min
within each treatment type were not significantly different from
one experiment to the other. Altogether, our data show that an
E2-induced effect can be reliably evidenced by measuring the L/s
ratio of 30 MRC5 cells 180min after treatment onset.
To further characterize this effect, we investigated the dose-
response of L/s ratio to E2 (Figure 3A). A decrease of this ratio
was observed for E2 concentrations from 10−7 to 10−10 M,
although the latter dose displayed a moderate effect. Applying
10−11 or 10−12 M did not induce any change in cell shape. As
shown above, MRC5 cells express the GPER membrane estrogen
receptor, but not the classical ERα nuclear receptor, suggesting
that the effect of E2 may be mediated by GPER. Consistently,
treating cells with the GPER synthetic agonist G-1 resulted in an
effect similar to that obtained with E2 treatment (Figure 3B). In
contrast, the GPER antagonist G-15, by itself innocuous on L/s
ratio, completely blocked the reduction of cell elongation exerted
by E2. Co-treatment with G-1 and G-15 resulted in a moderate
decrease of L/s ratio. However, further statistical analysis showed
that this effect was not significantly different from that of G-
15 alone. The effect of E2 was also blocked by another GPER
synthetic antagonist, G-36 (Figure S3). We conclude that MRC5
cell elongation reflects GPER activation status.
To further validate this hypothesis, we focused on a synthetic
compound, bisphenol A (BPA), reported to activate GPER (22,
23, 27). Cell viability tests indicated that exposure to 10−5 M
BPA did not significantly impact MRC5 cell survival (Table S2).
We then measured L/s ratio after treatment with various BPA
concentrations, with 10−6 M as the highest (Figure 4A). We
observed a time-dependent, dose-dependent reduction of L/s
ratio upon BPA exposure. Co-treatment with G-15 partially
impaired this effect (Figure 4B). As in the case of G-1 and
G-15 co-treatment above, statistical analysis showed that the
effect exerted by BPA+G-15 did not significantly differ from
that obtained with G-15 alone, indicating that BPA induces
morphological changes in a GPER-dependent manner. We next
studied the effects of three related bisphenol compounds. BPC
and BPF dose-dependently reduced the L/s ratio (Figures 4C,D),
an effect that was blocked by co-treatment with G-15 (Figure 4E),
indicating that these chemicals activate GPER. In contrast, BPE
was inactive at all concentrations tested (Figure 4F). We tested
the possibility that BPE could behave as a GPER-antagonist,
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FIGURE 2 | Statistical validation of the approach. (A) Cells were exposed to 10−7 M E2. 244 cells were individually analyzed for L/s ratio. (B) Medians of these ratios
at 0, 120, and 240min are indicated for reference by the turquoise lines (top to bottom, respectively). Hundred sets of 10, 30, 40, 50, 60, 80, 100, or 200 cells were
randomly sampled. Medians of L/s ratio were calculated for each extracted sample and are plotted. As expected, the dispersion of the medians decreases when
increasing the sample size. Medians of the 10-cell samples at a given time point are sometimes found overcrossing the 244-cell median at another time point. Thus,
the analysis of only 10 cells in a given experiment could lead to false negative results. (C) Statistical significances between exposure times were determined on the
same data set as in (B) (comprising the 244 original cells as well as the random samples of varying size). Friedman test was used to determine the global significance
(upper left graph), Wilcoxon signed-rank test was used when comparing two time points. Data are expressed as –log10 (pval). Significance obtained using the 244
cells original set is shown for reference as a blue line. Gray lines represent the lowest value considered as significant [i.e., –log10 (0.05)]. As expected, values increase
when increasing sample size. Thirty-cell sample size always produces significant pval, except when comparing time 120min to time 240min.
rather than agonist. However, BPE did not inhibit the effect
exerted by E2 (Figure 4G).
The data above indicate that the dynamic measure of L/s ratio
is a read-out for agonist or antagonist effects exerted on GPER.
This approach could thus be used as a screening method to
determine whether a given compound, including EDCs, targets
GPER. The effect of agonists would be blocked by co-treatment
with G-15, whereas antagonists would inhibit the action of E2.
To validate this possibility, we focused on 19 compounds (see
characteristics on Table S1), reported to act as EDCs, belonging
to different chemical families and with different applications. We
first examined their toxicity in MRC5 cells (Table S2). We then
evaluated these compounds at three different concentrations for
their capacity to impact on L/s ratio. For each compound, the
maximal concentration that we used was 10-fold less than the
highest non-toxic dose. All data are shown on Figures S4A–S
and summarized on Table 1. Four compounds (chlorpyrifos,
DEHP, dienochlor and quinoxyfen) induced a dose-dependent
reduction of the L/s ratio, to an extent that was comparable
to what observed with E2. Co-treatment with G-15 resulted in
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FIGURE 3 | Dynamic measurement of morphological changes induced by E2 in a GPER-dependent manner. (A) Cells were treated with the indicated concentration
of E2 and individually followed. Images generated with the Cytonote system were analyzed using ImageJ. Ratio long to short axis (L/s) was determined for individual
cells followed at the indicated times. Data are expressed relative to the median of L/s ratio at time 0. Graphs represent two pooled experiments, each including 30
cells. Statistical significance relative to time 0 was analyzed using Wilcoxon signed-rank test. Bottom graph summarizes the above data, with the relative medians
plotted as a function of time. For this graph, significance at time 180min was analyzed using Mann-Whitney test. (B) Same as above analyzing the effect of G-1 and
G-15 (GPER agonist and antagonist, respectively), alone or in combination as indicated. Bottom table displays the significance (estimated by Mann-Whitney tests) of
the indicated comparisons. *p < 0.05; **p < 0.005; ***p < 0.0005; ns: non significant.
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FIGURE 4 | GPER-dependent morphological changes induced by bisphenols. Same approach as Figure 3. (A) Effect of the indicated concentrations of bisphenol A
(BPA). Right graph summarizes the data, with the relative medians plotted as a function of time. For this graph, significance at time 180min was analyzed using
Mann-Whitney test. (B) Effects of G-15 co-treatment on BPA exposure. (C,D) Effects of bisphenol C (BPC, C) and F (BPF, D) at the indicated concentrations. (E)
Effect of G-15 pretreatment on BPC and BPF. (F) Effects of bisphenol E (BPE) at the indicated concentrations. (G) Effect of BPE pretreatment on E2 exposure. All
graphs represent pools of two independent experiments, each with n = 30 cells. Significance relative to time 0 was analyzed using Wilcoxon signed-rank test. *p <
0.05; **p < 0.005; ***p < 0.0005; ns: non significant. Tables displays the significances (estimated by Mann-Whitney tests) of the indicated comparisons.
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TABLE 1 | Effect of EDC exposure on L/s axis in MRC5 cells.
Effect at max. conc. Effect with G15 Effect with E2 Comments
Conc. Rel. med Rel. med Signif. vs. Signif. vs. Rel. med Signif. vs. Signif. vs.
(% at (% at EDC G15 (% at EDC E2
180min) 180min) only only 180min) only only
Chlorpyrifos 10−6 M 56.52 93.15 0.00003 0.419 nd Agonist
DEHP 10−6 M 61.39 94.84 0.0769 0.8479 nd Trend to agonist
Dienochlor 10−8 M 63.37 80.11 0.0145 0.097 nd Agonist
Quinoxyfen 10−7 M 66.29 92.94 0.0056 0.813 nd Agonist
4-Tert-Octylphenol 10−7 M 81.41 nd 69.37 0.0632 0.0381 Weak antagonist
Fenitrothion 10−6 M 82.04 nd 75.54 0.854 0.007 Antagonist
Tau-Fluvalinate 10−7 M 84.52 nd 55.12 0.0002 0.466 No effect
Bifenthrin 10−6 M 84.57 nd 54.73 7.901E-08 0.459 No effect
Chlorpyrifos-methyl 10−6 M 85.46 nd 60.99 0.024 0.3186 No effect
Cypermethrin 10−6 M 86.01 nd 88.74 0.532 0.0001 Antagonist
Dieldrin 10−6 M 86.24 nd 63.28 0.069 0.217 No effect
Ethylparaben 10−6 M 86.88 nd 69.94 0.0054 0.1691 No effect
Azoxystrobin 10−6 M 87.18 nd 69.32 0.3779 0.0003 Weak antagonist
Malathion 10−8 M 87.34 nd 94.06 0.879 0.00004 Antagonist
Imidacloprid 10−7 M 88.22 nd 68.07 0.014 0.195 No effect
Methylparaben 10−7 M 89.78 nd 59.60 7.382E-06 1.000 No effect
Penconazole 10−6 M 90.98 nd 65.29 0.006 0.268 No effect
Deltamethrin 10−6 M 91.31 nd 99.56 0.793 0.0001 Antagonist
Piperonyl-Butoxide 10−7 M 107.55 nd 63.78 2.929E-07 0.644 No effect
E2 10−7 M 51.9 84.77 0.00006 0.392 na Agonist
G15 10−7 M 94.21 na 84.77 0.00006 0.392 Antagonist
Cells were exposed to the indicated EDC. L/s ratios were determined for individual cells at 0 and 180min after EDC addition. Results (representing two experiments, each measuring 30
cells) are expressed as the median of L/s ratios at 180min relative to 0min. Where indicated, cells were co-treated with G-15 or E2. Significance was estimated using Mann-Whitney
test. Only the effect of the maximal concentration is shown for each EDC (see Figures S4A–S for complete data set). Effects observed with E2 or G-15 (complete results on Figure 3)
are displayed for reference. na, not applicable; nd, not determined.
effects that were i- not significantly different from that of G-
15 alone and ii- different from those observed when using each
compound individually (although significance was not reached
when comparing DEHP to DEHP+G-15). We concluded that
these four chemicals behaved as GPER agonists.
In contrast, when used alone, the other 14 compounds tested
here displayed a more moderate effect (or lack thereof) on L/s
ratio. Co-treatment with E2 revealed that some of these chemicals
behaved as antagonists. For example, the L/s ratios resulting
from malathion + E2 co-treatment were strongly different from
what obtained with E2 alone, but not different from what
observed with malathion alone. Oppositely, compounds such as
penconazole did not block the effect of E2, suggesting that they
are inactive on GPER.
DISCUSSION
In this report, we show that E2 induces a dose-dependent,
time-dependent morphological change in the MRC5 human
fibroblastic cell line. This leads to cell spreading which can be
quantified by measuring the ratio between the long and the short
cell axes. This effect is analogous to that previously observed
in human dermal fibroblasts (hDF) in primary culture (26) as
well as in breast cancer cells (28, 29). These actions of E2
do not depend on the classical nuclear estrogen receptors but
on GPER, a seven-transmembrane domain estrogen receptor,
as well as its downstream effectors ERK1/2. In hDF, this was
formally proven by the loss of E2 effects upon shRNA-mediated
GPER inactivation. As documented on Figure S1, transient
genetic inactivation of GPER is inefficient in MRC5 cells. Stably
inactivating the receptor (e.g., using a Crispr-Cas9 approach) is
difficult to envision given that the selection procedure would
likely exceed the low number of possible cell passages in culture.
Pharmacological approaches however show that the effects of
E2 rely on GPER. Indeed, this phenomenon can be mimicked
by supplementation with the synthetic GPER agonist G-1 and
the effects of E2 can be blocked by co-treatment with the GPER
antagonists G-15 and G-36.
The work presented here points to the possibility of a general
method to screen compounds for their capacity to signal through
GPER. Cell fixation and staining are not required, enabling
a dynamic monitoring of individual cells along treatment.
Furthermore, the use of the Cytonote lens-free device allows
to visualizing large fields and thus a large number of cells
with rapid image acquisition. Our statistical analyses show that
Frontiers in Endocrinology | www.frontiersin.org 8 August 2020 | Volume 11 | Article 547
Périan et al. GPER and Endocrine-Disrupting Chemicals
considering as few as 30 cells for 3 h is enough to reach
significance. The method used here appears very sensitive and,
in some cases, statistical tests can demonstrate that very small
changes in the L/s ratio are strongly significant at the population
level. However, the relevance of these small variations can be
questioned, in particular when no relation between dose and
response is observed. For instance, penconazole exerts a 10%
reduction of the L/s ratio at 10−8 M (with pval: 0.008), but not
at 10−6 or 10−10 M (see Figure S4Q). Similarly, dieldrin exerts
a 12–15% reduction of the relative L/s ratio with pval < 0.05
at all three concentrations tested (i.e., without dose-response
relations; see Figure S4K). Noteworthy, exposure to 10−12 M
BPA also results in a 12% reduction of the L/s ratio (with p ∼
0.01; Figure 4A). However, similarly to E2, BPA displays a clear
dose-dependent effect with a strong reduction of the L/s ratio
at maximal concentration (∼40% at 10−6 M). It thus cannot be
excluded that small variations in L/s ratio reflect experimental
noise rather than relevant signal. With such considerations in
mind, it appears sensible to consider only the compounds that
induce large variations (i.e., within the range of those observed
upon E2 exposure) in L/s ratio as GPER agonists. Altogether,
the GPER-specific method described here appears easy to set up,
robust and cheap.
As a proof-of-concept, we have performed a low throughput
screen in which 23 synthetic compounds were examined for
their capacity to modulate GPER activation. To the best of our
knowledge, most of these compounds have not been reported
for an effect on GPER (or lack thereof). Seven compounds
(bisphenols A, C and F, chlorpyrifos, DEHP, dienochlor and
quinoxyfen) were found to display agonist activities, according
to the above criterion. In support to this view, co-treatment with
G-15 abolished the cellular effect elicited by these chemicals. In
contrast, 16 compounds appeared inactive on cell morphology
when used alone. The capacity of six of these chemicals to
block the activities of E2 allows to consider them as GPER-
antagonists, whereas the remaining 11 do not appear to exert
any effect on GPER. Remarkably, structurally related compounds
do not necessarily fall into the same category. Consistent with
the current literature, BPA acted as a GPER agonist (22, 23,
27), as did BPC and BPF. In contrast, BPE, which only differs
from BPF and BPA by the presence or absence of a methyl
group (respectively), was completely inactive on GPER. In
this line, we also observed that chlorpyrifos and chlorpyrifos-
methyl displayed different behaviors (agonist and inactive,
respectively) toward GPER. In contrast, the related compounds
cypermethrin and deltamethrin both acted as GPER antagonists.
Structural studies will be required to determine the bases of
these differences and similarities. Our work identified EDCs
that positively or negatively modulate the activities of GPER in
normal human fibroblasts. On another hand, activation of GPER
in breast cancer-associated fibroblasts (CAFs) promotes cancer
progression (30–32). Whether the EDCs identified here also
modulate GPER activities in CAFs remains to be investigated, as
well as the consequences of these possible regulations.
In summary, we propose our approach as a potential screening
method to determine whether a given compound agonizes or
antagonizes GPER. Of note, an effect observed here of GPER
does not exclude possible actions on other receptors, such as ERα
or AR. Furthermore, the present assay is purely cell-based and
cannot be used to predict the effects of chemicals in vivo.
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Figure S1 | Analysis of MRC5 cells. (A) MRC5 cells were cultured in the presence
of untreated (FCS), or desteroidated serum-containing medium supplemented
with vehicle (DS) or 10−7 M E2. Proliferation is shown relative to day 0. Values are
the mean of two independent experiments performed in triplicate with error bars
representing SEM. Significance (relative to day 0) was analyzed using Student
t-test. ∗∗∗p < 0.0005; ns: non significant. Graph on the right zooms the lower part
of the left graph. (B) Expression of GPER mRNA (left) and protein (right) 72 h after
transfection with the indicated siRNA. Left: analysis was performed by real-time
PCR. Data are presented relative to siControl-treated samples and are the average
of two independent experiments performed in triplicate. Error bars represent SEM.
Significance (relative to siC) was analyzed using Student t-test. ∗p < 0.05; ∗∗p <
0.005; ns: non significant. Right: expression of the indicated proteins after
transfection with the indicated siRNA. Hsp90 was used as a loading control.
Figure S2 | Validation of the Cytonote approach in MRC5 cells. (A) Cells were
seeded in untreated serum-containing medium (FCS) then switched to DMEM
medium in the absence of serum. Graph represents a single experiment with n =
30. (B) Cells were treated with 10−7 M E2. Graph represents a pool of two
independent experiments, each with n = 30. (C) Cells were treated with 1/1,000
(vol/vol) DMSO. Graph represents a pool of two independent experiments, each
with n = 30. (D) Cells were treated with DMSO (1/1,000 vol/vol) or 10−7 M E2.
Each graph represent a single experiment with n = 30. Lower graph presents the
relative median at 180min (expressed as % from time 0) for each experiment.
Global pval comparing all DMSO or all E2 treatment was calculated using
Kruskal-Wallis test. Data on graphs are expressed relative to the median of the L/s
ratio at time 0. Statistical significance was analyzed using Wilcoxon signed-rank
test. ∗p < 0.05; ∗∗p < 0.005; ∗∗∗p < 0.0005; ns: non significant.
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Figure S3 | Antagonistic activities of G-36. Cells were treated with E2 and/or the
GPER antagonist G-36 and analyzed at the indicated time. Statistical significance
was determined using Wilcoxon signed-rank test. ∗p < 0.05; ∗∗p < 0.005; ∗∗∗p <
0.0005; ns: non significant. Tables displays the significances (estimated by
Mann-Whitney tests) of the indicated comparisons.
Figure S4 | Morphological changes induced by endocrine disrupting compounds
on MRC5 cells. Cells were treated with the indicated compounds at the various
concentrations. (A–D) Compounds, significantly inducing a morphological change
in MRC5, were also used in combination with the GPER antagonist G-15. (E–S)
Compounds that did not significantly induce any morphological change were also
used in combination with E2. Data are also summarized on Table 1. All graphs
represent two pooled independent experiments, each with n = 30. Statistical
significance was determined using Wilcoxon signed-rank test. ∗p < 0.05; ∗∗p <
0.005; ∗∗∗p < 0.0005; ns: non significant.
Table S1 | Characteristics of the compounds used in this study.
Table S2 | Evaluation of cell viability after exposure to the compounds used in this
study. Cell number was estimated after 48 h treatment with the indicated
compound and expressed relative (%) to treatment with vehicle (DMSO). Results
represent mean of two experiments performed in triplicate and are expressed
relative (%) to treatment with vehicle ± s.e.m. Significance was estimated used
Student t-test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.005; ns: not significant. nd: not
determined.
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